Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing

Cited by (1,000)

Items 201–300 of 1,000

1. COMPASS Ascending: Emerging clues regarding the roles of MLL3/KMT2C and MLL2/KMT2D proteins in cancer
   Richard J. Fagan, Andrew K. Dingwall · 2019 · Cancer Letters
2. Squamous Cell Lung Cancer: From Tumor Genomics to Cancer Therapeutics
   David R. Gandara, Peter S. Hammerman, Martin L. Sos, Primo N. Lara, Fred R. Hirsch · 2015 · Clinical Cancer Research
3. Inhibitor-Sensitive FGFR2 and FGFR3 Mutations in Lung Squamous Cell Carcinoma
   Rachel G. Liao, Joonil Jung, Jeremy H. Tchaicha, Matthew D. Wilkerson, Andrey Sivachenko, Ellen M. Beauchamp, Qingsong Liu, Trevor J. Pugh, Chandra Sekhar Pedamallu, David Neil Hayes et al. · 2013 · Cancer Research
4. BRAF in non-small cell lung cancer (NSCLC): Pickaxing another brick in the wall
   Alessandro Leonetti, Francesco Facchinetti, Giulio Rossi, Roberta Minari, Antonia Conti, Luc Friboulet, Marcello Tiseo, David Planchard · 2018 · Cancer Treatment Reviews
5. Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer
   Gerber, David E., Camidge, D. Ross, Morgensztern, Daniel, Cetnar, Jeremey, Kelly, Ronan J., Ramalingam, Suresh S., Spigel, David R., Jeong, Woondong, Scaglioni, Pier P., Zhang, Song et al. · 2020 · Lung Cancer
6. MAX Inactivation in Small Cell Lung Cancer Disrupts MYC–SWI/SNF Programs and Is Synthetic Lethal with BRG1
   Octavio A. Romero, Manuel Torres-Diz, Eva Pros, Suvi P. Savola, Antonio Gómez, Sebastián Morán, Carmen Sáez, Reika Iwakawa, Alberto Villanueva, Luis M. Montuenga et al. · 2013 · Cancer Discovery
7. Dysregulation and therapeutic targeting of RNA splicing in cancer
   Robert F. Stanley, Omar Ibrahim Abdel-Wahab · 2022 · Nature Cancer
8. MAPK pathway activity plays a key role in PD‐L1 expression of lung adenocarcinoma cells
   Thijs S Stutvoet, Arjan Kol, Elisabeth G.E. de Vries, Marco de Bruyn, Rudolf S.N. Fehrmann, Anton G.T. Terwisscha van Scheltinga, Steven de Jong · 2019 · The Journal of Pathology
9. The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC)
   Ravi Salgia, Rebecca R. Pharaon, Isa Mambetsariev, Arin Nam, Martin Sattler · 2021 · Cell Reports Medicine
10. The cancer COMPASS: navigating the functions of MLL complexes in cancer
    David J. Ford, Andrew K. Dingwall · 2015 · Cancer Genetics
11. A step-by-step microRNA guide to cancer development and metastasis
    Georgios S. Markopoulos, Eugenia Roupakia, Maria Tokamani, Evangelia Chavdoula, Maria Hatziapostolou, Christos Polytarchou, Kenneth B. Marcu, Athanasios G. Papavassiliou, Raphael Sandaltzopoulos, Evangelos Kolettas · 2017 · Cellular Oncology
12. Molecular histology of lung cancer: From targets to treatments
    Steven L. Wood, Maria Pernemalm, Philip A.J. Crosbie, Anthony David Whetton · 2015 · Cancer Treatment Reviews
13. KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer
    Krall, Elsa B, Wang, Belinda, Munoz, Diana M, Ilic, Nina, Raghavan, Srivatsan, Niederst, Matthew J, Yu, Kristine, Ruddy, David A, Aguirre, Andrew J, Kim, Jong Wook et al. · 2017 · eLife
14. DeepDSC: A Deep Learning Method to Predict Drug Sensitivity of Cancer Cell Lines
    Min Li, Yake Wang, Ruiqing Zheng, Xinghua Mindy Shi, Yaohang Li, Fang‐Xiang Wu, Jianxin Wang · 2019 · IEEE Transactions on Computational Biology and Bioinformatics
15. Lung cancer chemoprevention: current status and future prospects
    Robert L. Keith, York E. Miller · 2013 · Nature Reviews Clinical Oncology
16. ARID1A loss in cancer: Towards a mechanistic understanding
    Radhika Mathur · 2018 · Pharmacology & Therapeutics
17. The pathogenicity of splicing defects: mechanistic insights into pre‐mRNA processing inform novel therapeutic approaches
    Élisabeth Daguenet, Gwendal Dujardin, Juan Valcárcel · 2015 · EMBO Reports
18. SMARCA4 and Other SWItch/Sucrose NonFermentable Family Genomic Alterations in NSCLC: Clinicopathologic Characteristics and Outcomes to Immune Checkpoint Inhibition
    Joao V. Alessi, Biagio Ricciuti, Liam Flinn Spurr, Hersh V. Gupta, Yvonne Y. Li, Carolyn Glass, Mizuki Nishino, Andrew D. Cherniack, James R. Lindsay, Bijaya Sharma et al. · 2021 · Journal of Thoracic Oncology
19. Splicing factor mutations and cancer
    Yoshida, Kenichi, Ogawa, Seishi · 2014 · WIREs RNA
20. Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: Prevalence, clinical correlates, and prognostic relevance
    Mrinal M. Patnaik, Terra L. Lasho, Christy M. Finke, Curtis A. Hanson, Janice M. Hodnefield, Ryan A. Knudson, Rhett P. Ketterling, Animesh Dev Pardanani, Ayalew Tefferi · 2012 · American Journal of Hematology
21. RAS-MAPK pathway epigenetic activation in cancer: miRNAs in action
    Julien Masliah‐Planchon, Simon Garinet, Éric Pasmant · 2015 · Oncotarget
22. SAMHD1‐dependent retroviral control and escape in mice
    Jan Rehwinkel, Jonathan Maelfait, Anne Bridgeman, Rachel E. Rigby, Bruce E. Hayward, Rachel A. Liberatore, Paul D. Bieniasz, Greg J. Towers, Luís F. Moita, Yanick Joseph Crow et al. · 2013 · The EMBO Journal
23. Clinicopathologic Characteristics of BRG1-Deficient NSCLC
    Ibiayi Dagogo‐Jack, Alexa Betzig Schrock, Marina Kem, Nicholas A. Jessop, Jessica Lee, Siraj Mahamed Ali, Jeffrey S. Ross, Jochen K. Lennerz, Alice Tsang Shaw, Mari A. Mino-Kenudson · 2020 · Journal of Thoracic Oncology
24. Point mutation E1099K in MMSET/NSD2 enhances its methyltranferase activity and leads to altered global chromatin methylation in lymphoid malignancies
    Jon A. Oyer, Xiaoxiao Huang, Yupeng Zheng, Joon Young Shim, Teresa Ezponda, Zachary Carpenter, Maddalena Allegretta, C I Okot-Kotber, Jay Pravin Patel, Ashley F. Melnick et al. · 2013 · Leukemia
25. RNA components of the spliceosome regulate tissue- and cancer-specific alternative splicing
    Heidi Dvinge, Jamie Guenthoer, Peggy L. Porter, Robert K. Bradley · 2019 · Genome Research
26. Advances in computational approaches for prioritizing driver mutations and significantly mutated genes in cancer genomes
    Feixiong Cheng, Junfei Zhao, Zhongming Zhao · 2015 · Briefings in Bioinformatics
27. SMARCA4 /BRG1 Is a Novel Prognostic Biomarker Predictive of Cisplatin-Based Chemotherapy Outcomes in Resected Non–Small Cell Lung Cancer
    Erica Hlavin Bell, Arup R. Chakraborty, Xiaokui Molly Mo, Ziyan Liu, Konstantin Shilo, Simon Kirste, Petra Stegmaier, Maureen McNulty, Niki Karachaliou, Rafael Rosell et al. · 2015 · Clinical Cancer Research
28. A quantitative and multiplexed approach to uncover the fitness landscape of tumor suppression in vivo
    Zoë N Rogers, Christopher D. McFarland, Ian P. Winters, Santiago Naranjo, Chen-Hua Chuang, Dmitri A. Petrov, Monte M. Winslow · 2017 · Nature Methods
29. Disruption of STAT3 signalling promotes KRAS-induced lung tumorigenesis
    Beatrice Grabner, Daniel Schramek, Kristina M. Mueller, Herwig Peter Moll, Jasmin Svinka, Thomas Hoffmann, Eva Bauer, Leander Blaas, Natascha Hruschka, Katalin Zboray et al. · 2015 · Nature Communications
30. Targeted sequencing reveals clonal genetic changes in the progression of early lung neoplasms and paired circulating DNA
    Evgeny Izumchenko, Xiaofei Chang, Mariana Brait, Elana Judith Fertig, Luciane Tsukamoto Kagohara, Atul Bedi, Luigi Marchionni, Nishant Agrawal, Rajani K. Ravi, Siân Jones et al. · 2015 · Nature Communications
31. Utility of Genomic Assessment of Blood-Derived Circulating Tumor DNA (ctDNA) in Patients with Advanced Lung Adenocarcinoma
    Maria Clemence Schwaederle, Sandip Pravin Patel, Hatim Husain, Megumi Ikeda, Richard Burnham Lanman, Kimberly C. Banks, AmirAli H. Talasaz, Lyudmila A. Bazhenova, Razelle Kurzrock · 2017 · Clinical Cancer Research
32. Combined activation of MAP kinase pathway and β-catenin signaling cause deep penetrating nevi
    Iwei Yeh, Ursula E. Lang, Emeline Durieux, Meng Kian Tee, Aparna Jorapur, Alan Hunter Shain, Véronique Haddad, Daniel Pissaloux, Xu Chen, Lorenzo Cerroni et al. · 2017 · Nature Communications
33. Protein Arginine Methyltransferase 5 (PRMT5) Inhibitors in Oncology Clinical Trials: A review
    Kavanya Feustel, Gerald Steven Falchook · 2022 · Journal of Immunotherapy and Precision Oncology
34. EGFR Fusions as Novel Therapeutic Targets in Lung Cancer
    Konduri, Kartik, Gallant, Jean-Nicolas, Chae, Young Kwang, Giles, Francis J., Gitlitz, Barbara J., Gowen, Kyle, Ichihara, Eiki, Owonikoko, Taofeek K., Peddareddigari, Vijay, Ramalingam, Suresh S. et al. · 2016 · Cancer Discovery
35. MAP2K1 ( MEK1 ) Mutations Define a Distinct Subset of Lung Adenocarcinoma Associated with Smoking
    Maria E. Arcila, Alexander Edward Dela Cruz Drilon, Brooke E. Sylvester, Christine Marie Lovly, Laetitia A Borsu, Boris A. Reva, Mark G. Kris, David B. Solit, Marc Ladanyi · 2014 · Clinical Cancer Research
36. Control of Alveolar Differentiation by the Lineage Transcription Factors GATA6 and HOPX Inhibits Lung Adenocarcinoma Metastasis
    William K.C. Cheung, Minghui Zhao, Zongzhi Z. Liu, Laura E. Stevens, Paul D. Cao, Justin Edwin Fang, Thomas F. Westbrook, Don X. Nguyen · 2013 · Cancer Cell
37. Treatment of NRAS-mutant melanoma
    Johnson, Douglas B., Puzanov, Igor · 2015 · Current Treatment Options in Oncology
38. Genetic and epigenetic drivers of neuroendocrine tumours (NET)
    Annunziata Di Domenico, Tabea Wiedmer, Ilaria Marinoni, Aurel A. Perren · 2017 · Endocrine Related Cancer
39. Atlas of Genetics and Cytogenetics in Oncology and Haematology
    2011 · Atlas of Genetics and Cytogenetics in Oncology and Haematology
40. Molecularly Targeted Therapies in Non–Small-Cell Lung Cancer Annual Update 2014
    Daniel Morgensztern, Meghan J. Campo, Suzanne Eleanor Dahlberg, Robert Charles Doebele, Edward B. Garon, David E. Gerber, Sarah B. Goldberg, Peter S. Hammerman, Rebecca Suk Heist, Thomas A. Hensing et al. · 2015 · Journal of Thoracic Oncology
41. Mechanisms of resistance to targeted therapy and immunotherapy in non-small cell lung cancer: promising strategies to overcoming challenges
    Yuchu Xiang, Xudong Liu, Yifan Wang, Dawei Zheng, Qiuxing Meng, Lingling Jiang, Sha Yang, Sijia Zhang, Xin Zhang, Yan Liu et al. · 2024 · Frontiers in Immunology
42. BRG1/SMARCA4 Inactivation Promotes Non–Small Cell Lung Cancer Aggressiveness by Altering Chromatin Organization
    Tess Orvis, Austin J. Hepperla, Vonn Walter, Shujie Song, Jeremy M. Simon, Joel S. Parker, Matthew D. Wilkerson, Nisarg R. Desai, Michael B. Major, David Neil Hayes et al. · 2014 · Cancer Research
43. Burden of Nonsynonymous Mutations among TCGA Cancers and Candidate Immune Checkpoint Inhibitor Responses
    Leandro Machado Colli, Mitchell J. Machiela, Timothy A. Myers, Lea Jessop, Kai F. Yu, Stephen Jacob Chanock · 2016 · Cancer Research
44. Human Lung Adenocarcinoma-Derived Organoid Models for Drug Screening
    Zhichao Li, Youhui Qian, Wujiao Li, Lisa Liu, Lei Yu, Xia Liu, Guodong Wu, Youyu Wang, Weibin Luo, Fuyuan Fang et al. · 2020 · iScience
45. Inactivating CUX1 mutations promote tumorigenesis
    Chi C Wong, Sancha Martin, Alistair G. Rust, Mamunur Rashid, Constantine Alifrangis, Ludmil B. Alexandrov, Jessamy C. Tiffen, Christina Kober, Anthony Richard Green, Charles E. Massie et al. · 2013 · Nature Genetics
46. Single-cell analysis of somatic mutations in human bronchial epithelial cells in relation to aging and smoking
    Huang, Zhenqiu, Sun, Shixiang, Lee, Moonsook, Maslov, Alexander Y., Shi, Miao, Waldman, Spencer, Marsh, Ava, Siddiqui, Taha, Dong, Xiao, Peter, Yakov et al. · 2022 · Nature Genetics
47. Treatment of lung adenocarcinoma by molecular-targeted therapy and immunotherapy
    Motonobu Saito, Hiroyuki Y. Suzuki, Koji Kono, Seiichi Takenoshita, Takashi Kohno · 2017 · Surgery Today
48. Identification and Validation of a Novel Signature Based on NK Cell Marker Genes to Predict Prognosis and Immunotherapy Response in Lung Adenocarcinoma by Integrated Analysis of Single-Cell and Bulk RNA-Sequencing
    Peng Song, Wenbin Li, Lei Guo, Jianming Ying, Shugeng Gao, Jié He · 2022 · Frontiers in Immunology
49. U2AF35(S34F) Promotes Transformation by Directing Aberrant ATG7 Pre-mRNA 3′ End Formation
    Sung Mi Park, Jianhong Ou, Lynn Chamberlain, Tessa M. Simone, Huan Yang, Ching-Man A. Virbasius, Abdullah Mahmood Ali, Lihua Julie Zhu, Siddhartha Mukherjee, Azra Raza et al. · 2016 · Molecular Cell
50. Emerging roles of spliceosome in cancer and immunity
    Hui Yang, Bruce Beutler, Duanwu Zhang · 2021 · Protein & Cell
51. Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implications
    Teresa L. Helsten, Maria Clemence Schwaederle, Razelle Kurzrock · 2015 · Cancer and Metastasis Reviews
52. Association of tumor TROP2 expression with prognosis varies among lung cancer subtypes
    Kentaro Inamura, Yusuke Yokouchi, Maki Kobayashi, Hironori Ninomiya, Rie Sakakibara, Sophia Subat, Hiroko Nagano, Kimie Nomura, Sakae Okumura, Tomoko Shibutani et al. · 2017 · Oncotarget
53. Genetic and epigenetic intratumor heterogeneity impacts prognosis of lung adenocarcinoma
    Xing Hua, Zhao Wei, Angela Cecilia Pesatori, Dario Consonni, Neil E. Caporaso, Tongwu Zhang, Bin Zhu, Mingyi Wang, Kristine M. Jones, Belynda D. Hicks et al. · 2020 · Nature Communications
54. Distinct tumor-infiltrating lymphocyte landscapes are associated with clinical outcomes in localized non-small-cell lung cancer
    Lorenzo Federico, Daniel James McGrail, Salah-Eddine Bentebibel, Cara Haymaker, A. Ravelli, Marie‐Andrée Forget, Tatiana V. Karpinets, Peixin Jiang, Alexandre Reuben, Marcelo Vailati Negrao et al. · 2021 · Annals of Oncology
55. The prognostic effects of somatic mutations in ER-positive breast cancer
    Obi L. Griffith, Nicholas C. Spies, Meenakshi Anurag, Malachi Griffith, Jingqin Rosy Luo, Dongsheng Tu, Belinda Jane Yeo, Jason Kunisaki, Christopher A. Miller, Kilannin Krysiak et al. · 2018 · Nature Communications
56. Prospective Analysis of Oncogenic Driver Mutations and Environmental Factors: Japan Molecular Epidemiology for Lung Cancer Study
    Tomoya Kawaguchi, Yasuhiro Koh, Masahiko Ando, Norimasa Ito, Sadanori Takeo, Hirofumi Adachi, Tsutomu Tagawa, Seiichi Kakegawa, Motohiro Yamashita, Kazuhiko Kataoka et al. · 2016 · Journal of Clinical Oncology
57. Insertions and Deletions Target Lineage-Defining Genes in Human Cancers
    Marcin B. Imielinski, Guangwu Guo, Matthew M. Meyerson · 2017 · Cell
58. Aberrantly activated claudin 6 and 18.2 as potential therapy targets in non‐small‐cell lung cancer
    Patrick Micke, Johanna Sofia Margareta Mattsson, Karolina Edlund, Miriam Lohr, Karin Jirström, Anders Berglund, Johan Botling, Jörg Rahnenführer, Millaray Marincevic, Fredrik Pontén et al. · 2014 · International Journal of Cancer
59. Reduced expression of the chromatin remodeling gene ARID1A enhances gastric cancer cell migration and invasion via downregulation of E-cadherin transcription
    Haibo Yan, Xuefei Wang, Qian Zhang, Zhaoqing Tang, Ying-Hua Jiang, Huizhi Fan, Yihong Sun, Pengyuan Yang, Feng Liu · 2013 · Carcinogenesis
60. Rhabdoid Tumor Predisposition Syndrome
    Simone Treiger Sredni, Tadanori Tomita · 2014 · Pediatric and Developmental Pathology
61. Clinical Analysis and Interpretation of Cancer Genome Data
    Eliezer M. Van Allen, Nikhil Wagle, Mia Alyce Levy · 2013 · Journal of Clinical Oncology
62. Molecular Pathology of Primary Non-small Cell Lung Cancer
    David Ilan Suster, Mari A. Mino-Kenudson · 2020 · Archives of Medical Research
63. Role of KEAP1/NFE2L2 Mutations in the Chemotherapeutic Response of Patients with Non–Small Cell Lung Cancer
    Youngtae Jeong, Jessica A. Hellyer, Henning Stehr, Ngoc T. Hoang, Xiaomin Niu, Millie Snigdha Das, Sukhmani Kaur Padda, Kavitha J. Ramchandran, Joel W. Neal, Heather A. Wakelee et al. · 2019 · Clinical Cancer Research
64. A Personalized Treatment for Lung Cancer: Molecular Pathways, Targeted Therapies, and Genomic Characterization
    Thomas A. Hensing, Apoorva Chawla, Rishi Batra, Ravi Salgia · 2013 · Advances in experimental medicine and biology
65. State of the Art: Response Assessment in Lung Cancer in the Era of Genomic Medicine
    Mizuki Nishino, Hiroto Hatabu, Bruce Evan Johnson, Theresa C. McLoud · 2014 · Radiology
66. p73 regulates serine biosynthesis in cancer
    Ivano Amelio, Elke Katrin Markert, Alessandro Rufini, Alexey V. Antonov, Berna S. Sayan, Paola Tucci, Massimiliano Agostini, Tommaso Claudio Mineo, Arnold J. Levine, Gerry Melino · 2013 · Oncogene
67. Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma
    Marcin B. Imielinski, Heidi E. Greulich, Bethany Kaplan, Luiz Henrique Araujo, Joseph M. Amann, Leora Horn, Joan H. Schiller, Miguel Angel Villalona-Calero, Matthew M. Meyerson, David Paul Carbone · 2014 · Journal of Clinical Investigation
68. Tumor suppressor properties of the splicing regulatory factor RBM10
    Jordi Hernández, Elías Bechara, Dörte Schlesinger, Javier Delgado, Luis G. Serrano, Juan Valcárcel · 2016 · RNA Biology
69. Landscape of Combination Immunotherapy and Targeted Therapy to Improve Cancer Management
    Leandro Machado Colli, Mitchell J. Machiela, Han Zhang, Timothy A. Myers, Lea Jessop, Olivier Delattre, Kai F. Yu, Stephen Jacob Chanock · 2017 · Cancer Research
70. Metabolism and Epigenetic Interplay in Cancer: Regulation and Putative Therapeutic Targets
    Vera Miranda‐Gonçalves, Ana Lameirinhas, Rui Henrique, Cármen Jerónimo · 2018 · Frontiers in Genetics
71. EuRBPDB: a comprehensive resource for annotation, functional and oncological investigation of eukaryotic RNA binding proteins (RBPs)
    Jian‐You Liao, Bing Yang, Yu‐Chan Zhang, Xiaojuan Wang, Yushan Ye, Jing-Wen Peng, Zhi-Zhi Yang, Jiehua He, Yin Zhang, Kaishun Hu et al. · 2019 · Nucleic Acids Research
72. Pathogenesis and the Role of ARID1A Mutation in Endometriosis-related Ovarian Neoplasms
    Daichi Maeda, Ie‐Ming Shih · 2012 · Advances in Anatomic Pathology
73. Lessons Learned From Lung Cancer Genomics: The Emerging Concept of Individualized Diagnostics and Treatment
    Reinhard Buettner, Jürgen Wolf, Roman Kurt Thomas · 2013 · Journal of Clinical Oncology
74. MUC1-C integrates PD-L1 induction with repression of immune effectors in non-small-cell lung cancer
    Audrey Bouillez, Hasan N. Rajabi, Chengyue Jin, Mehmet Samur, Ashujit Tagde, M Alam, Masayuki Hiraki, Takahiro Maeda, Xiaochen Hu, Dennis O. Adeegbe et al. · 2017 · Oncogene
75. High expression of SMARCA4 or SMARCA2 is frequently associated with an opposite prognosis in cancer
    Jose Antonio Guerrero-Martinez, José C. Reyes · 2018 · Scientific Reports
76. Genomic Profiling of Lung Adenocarcinoma in Never-Smokers
    Siddhartha Devarakonda, Yize Li, Fernanda Martins Rodrigues, Sumithra Sankararaman, Humam Kadara, Chandra Goparaju, Irena Lanc, Kymberlie Pepin, Saiama N. Waqar, Daniel Morgensztern et al. · 2021 · Journal of Clinical Oncology
77. SMARCA4: Current status and future perspectives in non-small-cell lung cancer
    Yumeng Tian, Lu Xu, Xin Li, Heming Li, Mingfang Zhao · 2022 · Cancer Letters
78. Genomic Alterations in Fatal Forms of Non-Anaplastic Thyroid Cancer: Identification of MED12 and RBM10 as Novel Thyroid Cancer Genes Associated with Tumor Virulence
    Tihana Ibrahimpašić, Bin Xu, Iñigo Landa, Snjezana Doğan, Sumit Middha, Venkatraman Seshan, Shyam Deraje, Diane L. Carlson, Jocelyn C. Migliacci, Jeffrey A. Knauf et al. · 2017 · Clinical Cancer Research
79. Identification of recurrent FGFR3 fusion genes in lung cancer through kinome‐centred RNA sequencing
    Ian J. Majewski, Lorenza Mittempergher, N. Davidson, Astrid R. Bosma, Stefan M. Willems, Hugo M. Horlings, Iris de Rink, Liliana Greger, Gerrit K. J. Hooijer, Dennis D. G. C. Peters et al. · 2013 · The Journal of Pathology
80. RET fusion gene: Translation to personalized lung cancer therapy
    Takashi Kohno, Koji Tsuta, Katsuya Tsuchihara, Takashi Nakaoku, Kiyotaka Yoh, Kōichi Goto · 2013 · Cancer Science
81. Integrated genomic and transcriptomic analysis of human brain metastases identifies alterations of potential clinical significance
    Jodi M. Saunus, Michael C. J. Quinn, Ann‐Marie Patch, John V. Pearson, Peter J. Bailey, Kátia Nones, Amy E. McCart Reed, David K. Miller, Peter J. Wilson, Fares Al‐Ejeh et al. · 2015 · The Journal of Pathology
82. Mediator kinase module and human tumorigenesis
    Alison D. Clark, Marieke Oldenbroek, Thomas Boyer · 2015 · Critical Reviews in Biochemistry and Molecular Biology
83. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers
    Vural Tagal, Shuguang Wei, Wei Zhang, Rolf A. Brekken, Bruce A. Posner, Michael Peyton, Luc Girard, TaeHyun Hwang, David A. Wheeler, John Dorrance Minna et al. · 2017 · Nature Communications
84. MYC, MYCL, and MYCN as therapeutic targets in lung cancer
    Daniel Massó-Vallés, Marie-Ève Beaulieu, Laura Soucek · 2020 · Expert Opinion on Therapeutic Targets
85. Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS -Mutant Lung Adenocarcinoma
    Calles, Antonio, Sholl, Lynette M., Rodig, Scott J., Pelton, Ashley K., Hornick, Jason L., Butaney, Mohit, Lydon, Christine, Dahlberg, Suzanne E., Oxnard, Geoffrey R., Jackman, David M. et al. · 2015 · Clinical Cancer Research
86. Current therapy of KRAS-mutant lung cancer
    Ghimessy, Aron, Radeczky, Peter, Laszlo, Viktoria, Hegedus, Balazs, Renyi-Vamos, Ferenc, Fillinger, Janos, Klepetko, Walter, Lang, Christian, Dome, Balazs, Megyesfalvi, Zsolt · 2020 · Cancer and Metastasis Reviews
87. Integrated Omic analysis of lung cancer reveals metabolism proteome signatures with prognostic impact
    Lei Li, Yuhong Wei, Christine To, Chang‐Qi Zhu, Jiefei Tong, Nhu‐An Pham, Paul P. Taylor, Vladimir Ignatchenko, Alexandr Ignatchenko, Wen Zhang et al. · 2014 · Nature Communications
88. The tandem duplicator phenotype as a distinct genomic configuration in cancer
    Francesca Menghi, Koichiro Inaki, Xingyi Woo, Pooja Kumar, Krzysztof R. Grzȩda, Ankit Malhotra, Vinod Kumar Yadav, Hyunsoo Kim, Eladio J. Márquez, Duygu Ucar et al. · 2016 · Proceedings of the National Academy of Sciences
89. Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set
    Jason Roszik, Lauren Elaine Haydu, Kenneth R. Hess, Junna Oba, Aron Y. Joon, Alan E. Siroy, Tatiana V. Karpinets, Francesco C. Stingo, Veera Baladandayuthapani, Michael T. Tetzlaff et al. · 2016 · BMC Medicine
90. EGFR,KRAS,BRAFandALKgene alterations in lung adenocarcinomas: patient outcome, interplay with morphology and immunophenotype
    Arne Warth, Roland Penzel, Heike Lindenmaier, Regine Brandt, Albrecht Stenzinger, Esther Herpel, Benjamin Frank Goeppert, Michael Thomas, Felix J.F. Herth, Hendrik Dienemann et al. · 2013 · European Respiratory Journal
91. Autophagy modulates lipid metabolism to maintain metabolic flexibility for Lkb1 -deficient Kras -driven lung tumorigenesis
    Vrushank Dharmesh Bhatt, Khoosheh Khayati, Zhixian Sherrie Hu, Amy Shiu Lee, Wali Kamran, Xiaoyang Su, Jessie Yanxiang Guo · 2019 · Genes & Development
92. Distinct initiating events underpin the immune and metabolic heterogeneity of KRAS-mutant lung adenocarcinoma
    Best, Sarah A., Ding, Sheryl, Kersbergen, Ariena, Dong, Xueyi, Song, Ji-Ying, Xie, Yi, Reljic, Boris, Li, Kaiming, Vince, James E., Rathi, Vivek et al. · 2019 · Nature Communications
93. VarWalker: Personalized Mutation Network Analysis of Putative Cancer Genes from Next-Generation Sequencing Data
    Peilin Jia, Zhongming Zhao · 2014 · PLoS Computational Biology
94. Identification of Recurrent FGFR3–TACC3 Fusion Oncogenes from Lung Adenocarcinoma
    Marzia Capelletti, Michael E. Dodge, Dalia Ercan, Peter S. Hammerman, Seung-Il Park, Jhingook Kim, Hidefumi Sasaki, David M. Jablons, Doron Lipson, Lauren Young et al. · 2014 · Clinical Cancer Research
95. Molecular Typing of Lung Adenocarcinoma on Cytological Samples Using a Multigene Next Generation Sequencing Panel
    Aldo Scarpa, Katarzyna O. Sikora, Matteo Fassan, Anna Maria Rachiglio, Rocco Cappellesso, Davide Antonello, Eliana Amato, Andrea Mafficini, Matilde Lambiase, Claudia Esposito et al. · 2013 · PLoS ONE
96. Genome-wide DNA Methylation Analysis of Lung Carcinoma Reveals One Neuroendocrine and Four Adenocarcinoma Epitypes Associated with Patient Outcome
    Anna Karlsson, Mats Jönsson, Martin Lauss, Hans Brunnström, Per Jönsson, Åke Borg, Goran B Jönsson, Markus Ringnér, Maria Planck, Johan Staaf · 2014 · Clinical Cancer Research
97. Integrative analysis revealed the molecular mechanism underlying RBM10‐mediated splicing regulation
    Yongbo Wang, Andreas Gogol‐Döring, Hao Hu, Sebastian Fröhler, Yunxia Ma, Marvin Jens, Jonas Maaskola, Yasuhiro Murakawa, Claudia Quedenau, Markus Landthaler et al. · 2013 · EMBO Molecular Medicine
98. Large-scale analysis of branchpoint usage across species and cell lines
    Allison J. Taggart, Chien‐Ling Lin, Barsha Shrestha, Claire Heintzelman, Seong Won Kim, William Guy Fairbrother · 2017 · Genome Research
99. Bax/Bcl-2 Cascade Is Regulated by the EGFR Pathway: Therapeutic Targeting of Non-Small Cell Lung Cancer
    Manzar Alam, Shoaib Alam, Anas Shamsi, Mohd Adnan, Abdelbaset Mohamed Elasbali, Waleed Abu Al‐Soud, Mousa M. Alreshidi, Yousef MohammedRabaa Hawsawi, Anitha Tippana, Visweswara Rao Pasupuleti et al. · 2022 · Frontiers in Oncology
100. Splicing factor hnRNP A2 activates the Ras-MAPK-ERK pathway by controlling A-Raf splicing in hepatocellular carcinoma development
     Asaf Shilo, Vered Ben-Hur, Polina Denichenko, Ilan Stein, Eli Pikarsky, Jens Rauch, Walter Kölch, Lars Zender, Rotem Karni · 2014 · RNA